Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.3739
+0.0302 (8.79%)
At close: Jun 2, 2025, 4:00 PM
0.3737
-0.0002 (-0.05%)
Pre-market: Jun 3, 2025, 4:07 AM EDT
Mersana Therapeutics Employees
Mersana Therapeutics had 102 employees as of December 31, 2024. The number of employees decreased by 21 or -17.07% compared to the previous year.
Employees
102
Change (1Y)
-21
Growth (1Y)
-17.07%
Revenue / Employee
$333,392
Profits / Employee
-$725,578
Market Cap
46.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MRSN News
- 20 hours ago - Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewsWire
- 13 days ago - Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewsWire
- 18 days ago - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewsWire
- 27 days ago - Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewsWire
- 5 weeks ago - Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire